Sectra SECT-B.ST
SwedenHealthcare · Medical DevicesNasdaq Estocolmo · SEK
340.00 SEK (+16.4%)
3 analysts
XTB1.00 €affiliateOpen account ↗
Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗Interactive Brokers4.74 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Sectra AB is a Swedish medical technology company that develops and sells digital imaging systems (radiology, pathology) and IT solutions for the healthcare sector, with a business model based on recurring subscriptions and high customer retention.
Listed on Nasdaq Estocolmo · Symbol SECT-B.ST · STO: SECT-B · Currency SEK
Key points
from its scores- ✓Strong growth9.0
- ✓Very solid balance sheet8.2
- ✓High-quality business8.0
- ✕Demanding valuation1.5
- ✕Poor share-price trend4.6
AI analysis
bottom line, main risk, context and newsSectra's quality and growth are outstanding, but the current price already discounts years of future expansion, leaving little margin of safety for the investor.
Sectra AB shows impeccable financial health with net cash (Net Debt/EBITDA of -2.0), exceptional quality (ROE of 28.32%, ROIC of 30.33%) and very strong growth (revenue +25.8%, earnings +53.8%), but its valuation is extremely demanding (P/E of 90.75, EV/EBITDA of 67.32), which limits the investment appeal despite solid fundamentals.
The main risk is the extreme valuation (P/E of 90.75): any slowdown in revenue or earnings growth, or a shift in market sentiment towards growth stocks, could trigger a significant correction in the share price.
Context and risks
Sectra AB has no recent relevant news or material exposure to current macro factors. Its medical imaging and healthcare IT business has low sensitivity to interest rates, commodities, or geopolitical tensions, and its net cash balance sheet insulates it from external financial pressures.
Is Sectra stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 302% above the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 90.7 | 26.7 | +239% |
| EV / EBITDA | 67.3 | 14.5 | +365% |
| Price / book | 24.2 | 4.1 | +490% |
| Price / sales | 15.0 | 3.4 | +340% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 1.5 out of 10 (median for Healthcare: 4.7).
Average analyst target: 340.00 SEK, +16.4% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 8.0 (sector 5.5), Growth 9.0 (sector 6.6).
Classic formulas with standard assumptions (4.3% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 90.7
- Forward P/E
- 87.0
- EV / EBITDA
- 67.3
- Price / book
- 24.2
- Price / sales
- 15.0
- PEG
- 2.48
- Market cap
- 56.3B SEK
- Enterprise value
- 54.7B SEK
Profitability
- ROE
- 28.3%
- ROA
- 11.7%
- ROIC (approx.)
- 30.3%
- Gross margin
- 36.6%
- Operating margin
- 19.8%
- Net margin
- 16.5%
- Free cash flow
- 612.6M SEK
- FCF yield
- 1.1%
- Cash conversion
- 75%
Solvency
- Total debt
- 127.6M SEK
- Net debt
- −1.6B SEK
- Cash
- 1.8B SEK
- EBITDA
- 812.2M SEK
- Net debt / EBITDA
- −2.00
- Debt / equity
- 5.49
- Current ratio
- 1.75
- Quick ratio
- 1.60
Growth
- Revenue growth
- +25.8%
- Earnings growth
- +53.8%
- EPS (TTM)
- 3.22 SEK
- EPS (forward)
- 3.36 SEK
Dividend
- Dividend yield
- 0.4%
- Payout
- 34.2%
Risk and market
- Beta
- 0.90
- Analyst consensus
- none (3)
- Target price
- 340.00 SEK
- 52-week range
- 173.30 – 315.00
Recent news
All SECT-B.ST news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Sectra
Is Sectra stock cheap or expensive?
On P/E and EV / EBITDA, it trades 302% above the Healthcare median on average. Valuation score: 1.5 out of 10 (median for Healthcare: 4.7). Average analyst target: 340.00 SEK, +16.4% versus the price. This is not investment advice.
What score does Sectra get on MeridIAn Screener?
It scores 6.2 out of 10, rank 840 of 2,130 (better than 60% of the companies analysed). Its strongest category is Growth (9.0) and its weakest, Valuation (1.5). Analysis of 08/10/2026.
What is Sectra's P/E ratio?
Its P/E is 90.7: the share price equals 90.7 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 87.0.
How much is Sectra worth on the stock market?
Its market capitalisation is 56.3B SEK and its enterprise value, debt included, is 54.7B SEK.
How much debt does Sectra have?
It has more cash than debt: net cash of 1.6B SEK.
Does Sectra pay a dividend?
Yes: its dividend yield is 0.44% and it pays out 34% of its earnings.
How has Sectra stock performed over the last year?
It has fallen 2.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 173.30 and 315.00 SEK. Past performance does not guarantee future results.
What do analysts think of Sectra?
3 analysts cover it; their average recommendation is “none” and their average target is 340.00 SEK (+16.4% versus the price). It is an estimate, not market data.